b"Medicine & Researchrelapses and MRI lesions. The most commonpounds per month on average. The study found side effects were mild reactions at the injectionthose with higher BMI at the start tend to lose site.Thisnewdeliverymethodprovidesmore weight. GLP-1 agonists were generally exibility for patients and healthcare providerssafe, with 29 percent experiencing mild side while maintaining Ocrevus' established safetyeffects. Four patients developed new MRI and efficacy.lesions, and one had an MS relapse. Overall, Thrower -the medication was well-tolerated. The ndings In a Sept. 13 press release, Genentechwere published in the journal Neurological announced the FDA approval of OcrevusSciences. Zunova. Ocrevus is an FDA-approved anti-CD20 monoclonal antibody for relapsing and primaryThrower-Obesityisasignicanthealth progressive forms of MS. In its original form,issue in the U.S. and is of particular interest to the therapy is administered intravenously everythose living with MS. Obesity, especially in six months. These infusions typically last fromteen females, has been linked to a higher risk two to four hours. The newly approved versionfor developing MS. Obesity can also present are given just under the skin of the abdomen foradded challenges for mobility, transfers, and 10 minutes. Studies have shown the efficacyactivities for those living with MS. GLP-1 agonists and safety of the subcutaneous version arerepresent a class of drugs that are proving to be the same as those of the intravenous version.quite effective for weight loss. Some examples The main advantage of this new version is itof GLP-1 agonists include Ozempic, Trulicity, can be administered more rapidly than theand Mounjaro. But are they safe for people intravenous version. There is the possibilitywith MS? of local reactions at the injection site. TheseThis small, retrospective study looked at includeredness,swelling,anditching.We49 individuals with MS taking a GLP-1 agonist. would still do all the same screening labs andNo unexpected side effects were seen, and the monitoringlabswiththisnewlyapprovedGLP-1 agonists did not appear to negatively version.affect MS. In my personal experience, I have B cell-depleting therapies represent anhad many people with MS on GLP-1 agonists important class of MS disease-modifyingand have not seen anything unexpected.therapies. We now have two versions of Ocrevus,NewGait device helps x plus Briumvi and Kesimpta. Rituximab is notfoot drop walking problems FDA-approved for MS but is used off-label. Study: GLP-1 agonists safeThe study, conducted by Central Michigan for people with MSUniversityresearchersontheNewGait rehabilitative device explored its effectiveness This study, conducted by researchers atfor individuals with foot drop, a condition where the Department of Neurology, Massachusettslifting the front part of the foot is challenging General Hospital, looked at 49 MS patients,because of muscle weakness. The NewGait mostly women with relapsing MS who startedsystem, with the use of elastic bands and stable takingglucagon-likepeptide-1agonists,astraps, helped participants improve gait by medication often used for weight loss. Theseassisting dorsiexion and hip motion. The trial patients had an average body mass index ofshowed that wearing the device signicantly 39.7, indicating obesity, and lost about 1.03improved walkingpatternsandreduced msfocusmagazine.org 46"